WeiserMazars conducted a food and beverage study along with The Food Institute, AFI and Stagnito Business Information in 2013. The outcomes gave us potential insight into the future of the food and beverage market. A survey included manufacturers that range from annual sales of volumes of $10 million or less to more than $100 million. These results showed that sales increased 13% in average sales from the year before and the average profits increased by 17%. The next few years is said to be marked by “a period of anticipated growth due to a larger spike in sales.”
Barfresh Food Group Inc (OTCMKTS:BRFH) has been a part of this growth in the food market. The company develops, manufactures and distributes unique read-to-blend beverages. Some of these include shakes and smoothies that then get sent out to restaurants and food- chains. Barfresh Food Group Inc (OTCMKTS:BRFH) uses pre-packed ingredients that make new frozen beverages that are quick, cost-efficient, and healthier. The company has a special partnership with the leading food distributor in North America.
As previously mentioned, the company has been a part of the great growth in the food market. In August, they released great Q1 results; from July to August, they added added over 500 new customers, and have begun shipping to 137 new customers. “Our first quarter fiscal year 2016 sales increased 173% from the year ago quarter. In addition, sales in the first quarter exceeded the last three quarters of last year combined. Additionally, ordering trends for July and August have continued at a strong pace. Our business model is gaining momentum as we continue to hire sales representatives and achieve wins for our distribution business, and our large national accounts,” Riccardo Delle Coste, the Company’s CEO, said. Over the last three months, the BRFH has seen lows of $0.52 and has risen 52% to highs of $0.79.
Eanings Review: Rambus Inc. (NASDAQ:RMBS), Revlon Inc (NYSE:REV)
Revlon Inc(NYSE:REV) +2.5% after-hours after announcing that President and CEO Fabian Garcia is stepping down “to pursue other opportunities,” and Executive Vice Chair Paul Meister will oversee operations on an interim basis.
REV also says it expects Q4 revenues of $785M, below $801M from the year-earlier quarter but ahead of analyst consensus estimate of $743M, and a $60M-$80M net loss for the quarter due to a charge related to the recent tax law changes.
REV expects Q4 adjusted EBITDA of $110M-$115M vs. $115M analyst consensus.
CFO Chris Peterson also denies rumors that the company is considering a material asset transfer that would shield assets from lenders.
Rambus Inc.(NASDAQ:RMBS) shares are down 5.5% aftermarket following Q4 results that beat revenue estimates and met on EPS. In-line Q1 guidance (under ASC 605 accounting change) has revenue from $94M to $100M (consensus: $100.38M) and EPS from $0.17 to $0.23 (consensus: $0.18).
Revenue breakdown: Royalties, $77.9M (+10% Y/Y); Product, $8.5M (-27%); Contract and other revenue, $15.5M (+2%); Licensing billings, $76.6M (+18%).Key metrics: Non-GAAP operating margin, 31%; total operating expenses, $67.5M; cash and equivalents, $172.2M; cash flow from operations, $33.3M.
ADTRAN, Inc. (NASDAQ:ADTN) Hits New Lows After Issuing disappointing Earnings Forecast
ADTRAN, Inc.(NASDAQ:ADTN) slumped to a 52-week low after forecasting below consensus guidance for Q4, revising its revenue estimate downward to $125M from $155M-$165M earlier and seeing EPS of ~$0.01; analysts had expected EPS of ~$0.14 and revenue of $161.2M.
ADTN also projects Q1 to come in at roughly the same as Q4, misses analyst consensus of $167.5M.
CEO Tom Stanton says Q4 results have been hurt by a merger-related review, which ADTN expects to be completed in 60-90 days, and slowdown in the spending at a domestic Tier 1 customer.
MKM Partners analyst Michael Genovese believes the customer is CenturyLink (CTL -2%), which accounted for 24% of ADTN’s total sales in 2016.
The analyst thinks the weakness should prove temporary, adding that ADTN’s performance likely will accelerate into 2019 as the company stands to benefit from 5G spending; MKM trims its ADTN target price to $25 from $27 but keeps its Buy rating.
Big IPO Coming: Celator Pharmaceuticals Inc(NASDAQ:CPXX), Moleculin Biotech’s (MBRX)
Today at 10am Eastern, Moleculin Biotech ticker symbol MBRX will debut on the Nasdaq stock exchange and is being considered as one of the most highly anticipated IPO’s of 2016 by the street. The excitement and anticipation is arising from many experts saying that Moleculin Biotech’s (MBRX) drug annamycin is far superior to Celator Pharmaceuticals Inc(NASDAQ:CPXX) drug daunorubicin.
CPXX which has been bought out by Jazz Pharmaceuticals plc – Ordinary Shares(NASDAQ:JAZZ) for $1.5 Billion Dollars last week, share price ran from $1.6 to $31 in 2 months. Moleculin Biotech’s share structure is a 1.5m public float Priced at $6.